Overcoming challenges of ovarian cancer stem cells: novel therapeutic approaches. (Q37978771)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22278130 AND SRC:MED&resulttype=core&format=json

21 January 2020

title

Overcoming challenges of ovarian cancer stem cells: novel therapeutic approaches (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22278130 AND SRC:MED&resulttype=core&format=json

21 January 2020

1 reference

neoplastic stem cells

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22278130 AND SRC:MED&resulttype=core&format=json

21 January 2020

Cristóbal Aguilar

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22278130 AND SRC:MED&resulttype=core&format=json

21 January 2020

Santiago Domingo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22278130 AND SRC:MED&resulttype=core&format=json

21 January 2020

author name string

Emily Cecilia Rutledge

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22278130 AND SRC:MED&resulttype=core&format=json

21 January 2020

Ana M Martínez-Arroyo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22278130 AND SRC:MED&resulttype=core&format=json

21 January 2020

Juan José Hidalgo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22278130 AND SRC:MED&resulttype=core&format=json

21 January 2020

publication date

1 September 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22278130 AND SRC:MED&resulttype=core&format=json

Stem Cell Reviews and Reports

21 January 2020

published in

1 reference

26 August 2017

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22278130 AND SRC:MED&resulttype=core&format=json

21 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22278130 AND SRC:MED&resulttype=core&format=json

21 January 2020

page(s)

994-1010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22278130 AND SRC:MED&resulttype=core&format=json

Estimates of cancer incidence and mortality in Europe in 2008.

21 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Surgical management of recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Prospective identification of tumorigenic breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Prospective identification of tumorigenic prostate cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Phenotypic characterization of human colorectal cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Identification of pancreatic cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Identification and characterization of ovarian cancer-initiating cells from primary human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Epigenetic regulation of CD133 and tumorigenicity of CD133 ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Self-renewal and solid tumor stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Building a framework for embryonic microenvironments and cancer stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Neoadjuvant chemotherapy for the management of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

The response of CD24(-/low)/CD44 breast cancer-initiating cells to radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Cancer stem cell and cancer stemloids: from biology to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Cancer stem cells and chemoradiation resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Identification of selective inhibitors of cancer stem cells by high-throughput screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Immunity, Inflammation, and Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Macrophage diversity enhances tumor progression and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Mesenchymal stem cells within tumour stroma promote breast cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Severe hypoxia induces chemo-resistance in clinical cervical tumors through MVP over-expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Is cancer a disease of abnormal cellular metabolism? New angles on an old idea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Pharmacogenomics of platinum-based chemotherapy in NSCLC

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Erratum to: Functional and molecular characterisation of mammary side population cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Human endometrial side population cells exhibit genotypic, phenotypic and functional features of somatic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Clinical significance of side population in ovarian cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Cancer stem cells: are we missing the target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Drug transporters of platinum-based anticancer agents and their clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Intensive expression of Bmi-1 is a new independent predictor of poor outcome in patients with ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Pharmacogenomics of paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Cancer stem cells: an old idea--a paradigm shift

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Expression of recessive alleles by chromosomal mechanisms in retinoblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Clinical implications of p53 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Cellular stress response and apoptosis in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

A new cell line from human undifferentiated carcinoma of the ovary: establishment and characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Cancer induction by restriction of oncogene expression to the stem cell compartment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Human ovarian cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Ovarian cancer: a clinical challenge that needs some basic answers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Antibodies targeting cancer stem cells: a new paradigm in immunotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Expression of CD133-1 and CD133-2 in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

CD44: structure, function, and association with the malignant process.

21 January 2018

2 references

https://api.crossref.org/works/10.1007/S12015-011-9344-5

21 January 2018

12 December 2020

Prevalence of Epithelial Ovarian Cancer Stem Cells Correlates with Recurrence in Early-Stage Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

CD44, a therapeutic target for metastasising tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

CD44v6: a target for antibody-based cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Cancer stem cells in solid tumours: accumulating evidence and unresolved questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Cytotoxic activity of novel human monoclonal antibody MT201 against primary ovarian tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

ABC transporters in cancer: more than just drug efflux pumps.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Identification and targeting of cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Clinical study of 9-cis retinoic acid (LGD1057) in acute promyelocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Stem cell origin of cancer and differentiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

EZH2-mediated epigenetic repression of DNA repair in promoting breast tumor initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Will cancer stem cells provide new therapeutic targets?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Teratogens as anti-cancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Right on target: eradicating leukemic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Specific unsaturated fatty acids enforce the transdifferentiation of human cancer cells toward adipocyte-like cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

PPAR gamma and human metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Peroxisome proliferator-activated receptor-gamma agonists cause growth arrest and apoptosis in human ovarian carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

In vitro metformin anti-neoplastic activity in epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Nanoparticle therapeutics: an emerging treatment modality for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Small-molecule delivery by nanoparticles for anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Functionalized micellar systems for cancer targeted drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Integrin-assisted drug delivery of nano-scaled polymer therapeutics bearing paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Angiogenesis: an organizing principle for drug discovery?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

MicroRNA-200a inhibits CD133/1 ovarian cancer stem cells migration and invasion by targeting E-cadherin repressor ZEB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Origins and molecular pathology of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

The biology of ovarian cancer: new opportunities for translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Unmasking the complexities of mucinous ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Ovarian carcinoma pathology and genetics: recent advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Endometrioid epithelial ovarian cancer : 20 years of prospectively collected data from a single center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Ovarian surface epithelium: biology, endocrinology, and pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

A human colon cancer cell capable of initiating tumour growth in immunodeficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Overexpression of CD133 promotes drug resistance in C6 glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Immunohistochemical features of CD133 expression: association with resistance to chemoradiotherapy in rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Identification of gastric cancer stem cells using the cell surface marker CD44.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Immunohistochemical analysis of the S100A1, S100B, CD44 and Bcl-2 antigens and the rate of cell proliferation assessed by Ki-67 antibody in benign and malignant melanocytic tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

THY1 expression is associated with tumor suppression of human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Significance of CD90 cancer stem cells in human liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Expression of CD24 in clear cell renal cell carcinoma and its prognostic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Overexpression of CD24, c-myc and phospholipase 2A in prostate cancer tissue samples obtained by needle biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

The expression of dipeptidyl peptidase IV (DPPIV/CD26) is associated with enhanced chemosensitivity to paclitaxel in epithelial ovarian carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

A subpopulation of CD26 cancer stem cells with metastatic capacity in human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Proliferating cell nuclear antigen, survivin, and CD34 expressions in pancreatic cancer and their correlation with hypoxia-inducible factor 1alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Mobilized CD34 cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Properties of CD34 CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Targeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Inhibitors of topoisomerase II: structure-activity relationships and mechanism of action of podophyllin congeners.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Aldehyde dehydrogenase-expressing colon stem cells contribute to tumorigenesis in the transition from colitis to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12015-011-9344-5

Peroxisome proliferator-activated receptor alpha and gamma ligands inhibit the growth of human ovarian cancer

21 January 2018

1 reference

12 December 2020

Hyaluronic acid-paclitaxel: effects of intraperitoneal administration against CD44( ) human ovarian cancer xenografts.

1 reference

12 December 2020

The miR-200 family controls -tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients

1 reference

12 December 2020

Functional and molecular characterisation of mammary side population cells

1 reference

12 December 2020

Oxazaphosphorine-specific resistance in human MCF-7 breast carcinoma cell lines expressing transfected rat class 3 aldehyde dehydrogenase

1 reference

12 December 2020

The ABCG2 resistance network of glioblastoma

1 reference

12 December 2020

The Control of the Metabolic Switch in Cancers by Oncogenes and Tumor Suppressor Genes

1 reference

12 December 2020

A genetically engineered influenza A virus with ras-dependent oncolytic properties

1 reference

12 December 2020

Differentiation and reversal of malignant changes in colon cancer through PPARgamma

1 reference

12 December 2020

Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents.

1 reference

12 December 2020

THY1 is a candidate tumour suppressor gene with decreased expression in metastatic nasopharyngeal carcinoma.

1 reference

12 December 2020

CD133 expression defines a tumor initiating cell population in primary human ovarian cancer

1 reference

12 December 2020

Identification of a lineage of multipotent hematopoietic progenitors.

1 reference

12 December 2020

Foundations in cancer research. Chromosomes and cancer: the evolution of an idea.

1 reference

12 December 2020

Knockdown of SOD1 sensitizes the CD34 CML cells to imatinib therapy

1 reference

12 December 2020

HER-2/neu amplification and overexpression in endometrial carcinoma.

1 reference

12 December 2020

EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma

1 reference

12 December 2020

Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers.

1 reference

12 December 2020

1 reference

12 December 2020

Peroxisome proliferator activated receptor agonists

1 reference

12 December 2020

Expression of MDR1 in epithelial ovarian cancer and its association with disease progression

1 reference

12 December 2020

Identification of a cancer stem cell in human brain tumors

1 reference

12 December 2020

Management of women with newly diagnosed ovarian cancer

1 reference

12 December 2020

Glutathione peroxidase 3 is a candidate mechanism of anticancer drug resistance of ovarian clear cell adenocarcinoma

1 reference

12 December 2020

Transcriptome analysis of endometrial cancer identifies peroxisome proliferator-activated receptors as potential therapeutic targets

1 reference

12 December 2020

Expression of CD44S and CD44v5 is more common in stage III than in stage I serous ovarian carcinomas.

1 reference

12 December 2020

Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma.

1 reference

12 December 2020

Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer

1 reference

12 December 2020

High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody

1 reference

12 December 2020

P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer

1 reference

12 December 2020

CD44 expression indicates favorable prognosis in epithelial ovarian cancer

1 reference

12 December 2020

Peroxisome proliferator-activated receptor gamma and cancers

1 reference

12 December 2020

Enzymatic mechanisms of resistance to alkylating agents in tumor cells and normal tissues

1 reference

12 December 2020